High-volume infiltration analgesia in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial

Acta Anaesthesiol Scand. 2008 Nov;52(10):1331-5. doi: 10.1111/j.1399-6576.2008.01777.x.

Abstract

Background: High-volume infiltration analgesia may be effective with a low risk of side effects in hip and knee arthroplasty. The present placebo-controlled study was carried out to evaluate the analgesic effect of high-volume infiltration analgesia in bilateral total knee arthroplasty, along with a detailed description of the infiltration technique.

Methods: In a randomized, double-blind, placebo-controlled trial in 12 patients undergoing bilateral knee arthroplasty, saline or high-volume (170 ml) ropivacaine (0.2%) with epinephrine was infiltrated around each knee, with repeated doses administered through an intra-articular catheter for 24 h and pain and opioid requirements assessed for 48 h in a fast-track setting.

Results: Pain at rest and during movement was significantly reduced for up to 32 h with the high-volume local anesthetic infiltration technique. No major side effects were observed. The median hospital stay was 4 days.

Conclusion: High-volume infiltration analgesia is effective in knee arthroplasty and, due to its simplicity, may be preferable compared with other analgesic techniques in knee arthroplasty.

Trial registration: ClinicalTrials.gov NCT00408707.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amides / administration & dosage*
  • Analgesia / methods*
  • Anesthesia, Local / methods*
  • Anesthetics, Local / administration & dosage*
  • Arthroplasty, Replacement, Knee*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pain Measurement
  • Pain, Postoperative / prevention & control
  • Prospective Studies
  • Ropivacaine
  • Sodium Chloride / administration & dosage
  • Time Factors

Substances

  • Amides
  • Anesthetics, Local
  • Sodium Chloride
  • Ropivacaine

Associated data

  • ClinicalTrials.gov/NCT00408707